Immunogen (Immunogen) Pre-Tax Income : $-72.6 Mil (TTM As of Sep. 2023)

View and export this data going back to 1989. Start your Free Trial

What is Immunogen Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Immunogen's pretax income for the three months ended in Sep. 2023 was $29.6 Mil. Its pretax income for the trailing twelve months (TTM) ended in Sep. 2023 was $-72.6 Mil. Immunogen's pretax margin was 26.08%.

During the past 13 years, Immunogen's highest Pretax Margin was -25.24%. The lowest was -315.91%. And the median was -162.99%.

Immunogen Pre-Tax Income Historical Data

The historical data trend for Immunogen's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunogen Pre-Tax Income Chart

Immunogen Annual Data

Trend

Jun13

Jun14

Jun15

Jun16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Pre-Tax Income

Get a 7-Day Free Trial

-168.84

-104.13

-44.37

-139.30

-221.71

Immunogen Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Pre-Tax Income	Get a 7-Day Free Trial															-77.76	-57.79	-41.01	-3.37	29.58

Competitive Comparison of Immunogen's Pre-Tax Income

For the Biotechnology subindustry, Immunogen's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immunogen's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunogen's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Immunogen's Pre-Tax Income falls into.

Immunogen Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Immunogen's Pretax Income for the fiscal year that ended in Dec. 2022 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-220.893	+	3.347	+	-4.165	+	0	+	-2.8421709430404E-14
	=	-221.7

Immunogen's Pretax Income for the quarter that ended in Sep. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	25.956	+	-0.164	+	-3.593	+	7.383	+	3.5527136788005E-15
	=	29.6

Pre-Tax Income for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-72.6 Mil.

Immunogen (NAS:IMGN) Pre-Tax Income Explanation

Immunogen's Pretax Margin for the quarter that ended in Sep. 2023 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	29.582	/	113.425
	=	26.08%

During the past 13 years, Immunogen's highest Pretax Margin was -25.24%. The lowest was -315.91%. And the median was -162.99%.

Immunogen Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Immunogen's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunogen (Immunogen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunogen Inc (NAS:IMGN) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

IMGN:Mexico IMU:Germany

Address

830 Winter Street, Waltham, MA, USA, 02451

Website

https://www.immunogen.com

Immunogen Inc is a clinical-stage biotechnology company from the United States. Its focus is antibody-drug conjugate, or ADC, technology, which uses an antibody that fixes on a target (its antigen) found on tumor cells to deliver a specific cancer-killing agent.

Executives

Theresa Wingrove	officer: VP of Regulatory Affairs	IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451
Renee Lentini	officer: V.P.-Fin., Prin. Acctg. Off.	830 WINTER STREET, WALTHAM MA 02451
Stacy Ann Coen	officer: Chief Business Officer	11 RUSH POND RD, LAKEVILLE MA 02347
Kristine Peterson	director	AMARIN CORPORATION, MYSTIC PACKER BLDG., 12 ROOSEVELT AVENUE, MYSTIC CT 06355
Lauren White	officer: SVP, CFO and PFO	C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Mark J Enyedy	director, officer: Chief Executive Officer	C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121
Isabel Kalofonos	officer: SVP & CHIEF COMMERCIAL OFFICER	C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451
Michael Vasconcelles	officer: EVP R&D & MEDICAL AFFAIRS	C/O UNUM THERAPEUTICS, 200 CAMBRIDGEPARK DR., STE. 3100, CAMBRIDGE MA 02140
Daniel Char	officer: SVP & CHIEF LEGAL OFFICER	C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139
Kristen Harrington-smith	officer: SVP & Chief Commercial Officer	C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451
Tracey L Mccain	director	C/O BLUEPRINTS MEDICINES CORPORATION, 38 SIDNEY STREET, SUITE 200, CAMBRIDGE MA 02139
Helen M. Thackray	director	C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG MD 20879
David G Foster	officer: V.P.-Fin., Prin. Acctg. Off.	C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451
Susan Altschuller	officer: SVP and CFO	45 TENNYSON ST., SOMERVILLE MA 02145
Craig Barrows	officer: Vice-President,General Counsel	C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451